Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2026 Filed Mar 25, 2026 17:10 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 45,867 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001193125-26-124348 · ownership.xml · derivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 45,867 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 08:55 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 36,979 | $0.98 Strike: $0.98 | $36,239.42 |
DisclosureSEC source: 0000950170-25-048892 · ownership.xml · derivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 16:33 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 35,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038104 · ownership.xml · nonDerivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,015 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:43 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 139,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021407 · doc4.xml · nonDerivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,796 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:16 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 66,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-012921 · form4.xml · nonDerivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,441 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 17:35 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | ConversionSeries B Convertible Preferred Stock · Derivative | 15,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034643 · form4.xml · derivative · entry 2 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 17:35 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | ConversionCommon Stock | 2,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-034643 · form4.xml · nonDerivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date. F2 · balance_after: Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 19:47 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 42,191 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034426 · form4.xml · derivative · entry 1 FLAVIN JOHN L · CIK 0001126556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,191 Underlying: Common Stock · 42,191 shares Expires 2031-10-07 F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.